DURHAM, N.C., Aug. 21, 2024 /PRNewswire/ — Leader in comprehensive real-world evidence (RWE) and advanced analytical solutions, Target RWE, will share new findings on a sequential nested trial (SNT) study at the International Society for Pharmacoepidemiology (ISPE) annual meeting from August 24-28th in Berlin, Germany.
Titled “Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study,” the research compared an SNT emulation that indexes patients at treatment decision points to a typical trial that randomizes patients once (known as a single-point trial or SPT).
“Indexing patients at treatment decision points in SNT emulations can be an efficient approach to studying the effectiveness and safety of new treatments against a background standard of care. Our study illuminates some challenges with the interpreting of such studies,” said Target RWE Scientific Advisor, M. Alan Brookhart, PhD. “By accounting for differences in the patient visit process, it is possible to standardize results to improve their interpretability.”
The study, led by Chase Latour and Catie Wiener, used advanced Monte-Carlo simulation techniques that mirrored complex real-world clinical situations to assess the performance of different analytic techniques.
“Our research at ISPE 2024 represents a significant step forward in understanding the sequential nested trial design,” said Target RWE Chief Scientific Officer, Jennifer Christian, PharmD, PhD, FISPE. “We are excited to highlight Target RWE’s proven experience in applying next-generation epidemiological methods and rigorous statistics to inform strategic, data-driven decisions important to the drug development lifecycle.”
Other exciting activities at ISPE 2024 will include the induction of Dr. Christian as the incoming Vice President of Finance for ISPE during this year’s annual meeting where she previously served as Vice President of Finance – Elect since the 2023 annual meeting.
Follow us on X (@TargetRWE) and LinkedIn to keep up with the latest news!
About Target RWE
As the industry’s best-in-class, complete real-world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real-world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
Contact:
Kayla Slake
Senior Marketing Manager
kslake@targetrwe.com
984.234.0268 ext 205
SOURCE Target RWE
Black Book's 2025 survey highlights trends and investment priorities in healthcare IT, based on insights…
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating…
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis…
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and…
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension…
SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX:…